Drug Combination Details
| General Information of the Combination (ID: C77973) | |||||
|---|---|---|---|---|---|
| Name | Cucurbitacin I NP Info | + | Ionizing radiation Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Colon cancer
[ICD-11: 2B90]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| In-vitro Model | Cells derived from NSCLC patients | Non-small cell lung cancer | Homo sapiens | |||
| Experimental
Result(s) |
Targeting STAT3 signaling in CD133-positive NSCLC cells with cucurbitacin I suppressed CSC-like properties and enhanced chemoradiotherapy response. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Cucurbitacin I inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer-derived CD133-positive cells. Cancer. 2011 Jul 1;117(13):2970-85. | |||
